1.“Brain metastasis of non-small cell lung cancer. Survival analysis. ”J.Martin; JM.Garcia-BuenoJ.RifaA.Gonzalez; G.Esquerdo; J.Terrasa; A.Arrivi; O.Pons.21congress ESMO: Viena Noviembre 96.
2.“Cisplatin and Vinorelbine in advanced non small lung cancer.”J.Terrasa; J.Rifa; JM.GarciaBuenoA. Gonzalez; G.Esquerdo;J. Martin, A.Arrivi ;O.Pons. 21 congress of ESMO:Viena. Noviembre96.
3.“Tratamiento del carcinoma renal metastásico con inmunoterapia y5-fu.” JM.Garcia-Bueno; J.Martin; A.Arrivi; A.Gonzalez; G.Esquerdo; J.Terrasa; O.Pons; J.Rifa.. Oncología Nº 6 junio/1997 – vol.20
4.“Tratamiento del adenocarcinoma de recto estadios B2 y C.” J.Martin , JM.Garcia-Bueno; A.Gonzalez; G.Esquerdo; A.Arrivi; O.Pons; J.Terrasa; D.Aguiar; J.Rifa.Oncología Nº6 junio/1997 – vol.20 .
5.“Treatment with GM-CSF for chemotherapy induced febrile neutropenia”.JM. Garcia-bueno; G.Esquerdo; A.Gonzalez; D.Aguiar; J.Martin; A.Arrivi; J.Terrasa; R.Pazo; J.Rifa.Annals of Oncolgy Vol 9,1998 supl 4.
6.“Clinical benefit improvement with GEMCITABINE as first line therapy for patients with advanced PANCREAS CANCER”. H.Manzano; G.Esquerdo; J.Rifa; D.Aguiar; A.Arrivi; R.Pazo; J.Martin; J.Terrasa.. Annals of Oncolgy Vol 9,1998 supl 4.
7.Experiencia clínica con raltritexed en el tratamiento del carcinoma colorectal avanzado.H. Manzano, D. Aguiar, G.Esquerdo. Revista de Oncologia volumen 1, suplemento 1,1999
8. Adjuvant CMF Schedule as a Prognostic Factor in Patients with Early Breast Cancer: a Systematic Review and Regresion Análisis.E. Barrajon , L. Diez , G. Esquerdo. Proc Am Soc Clin Oncol 20: 2001 (abstr 1848)
9.Estudio fase II de la combinación de gemcitabina-carboplatino en el tratamiento de primera linea del carcinoma urotelial avanzado.C. Molins, O. Juan, A. Sanhez, G. Esquerdo. Revista de Oncologia volumen 5, suplemento 3,2003.
10.Estudio fase II de epirrubicina, cisplatino y tegafur oral modulado en cáncer gástrico avanzado.E. Gallar12do, E. Batiste, P.Escudero, C. Pericay, F.Losa, V. Alonso, JM. Campos, M. Gallen, G. Esquerdo. Revista de Oncologia volumen 5, suplemento 3,2003.
11.Estudio sobre tratamiento con epoetinum alfa pauta semanal (40000ui) en pacientes con cáncer.G. Esquerdo, C. LLorca, JM. Cervera. Revista de Oncologia volumen 5, suplemento 3,2003.
12.Epoetin alfa once weekly (40000 UI) in patients with stage IV cancer.Type I type II responders and refractary. Cervera JM, Esquerdo G, LLorca C. Optimizing cancer chemotherapy and hormonal therapy.The fourth Genolier-geneva-MSKCC CANCER CONFERENCE 2004.
13.Phase II study of epirubicin, cisplatin and modulated oral tegafur in advanced gastric cancer. On behalf of ACROSS cooperative group.E. Gallardo, E. Batiste, P. Escudero , J. Alfaro, C Pericay, F. Losa,G. Esquerdo. Annals of Oncology , volume 15, Supplement 3, 2004.
14.Triweekly-shedule of irinotecan and raltitrexed for firs-line treatment in advanced colorectal cancer. Analysis of a single institution treatment results. G.Esquerdo, C. LLorca, JM Cervera. Annals of Oncology , volume 15, Supplement 3, 20004
15.Gemcitabine-carboplatine as first line treatment for advanced urothelial carcinoma. C. Molins, O. Juan, G. Esquerdo. Annals of Oncology , volume 15, Supplement 3, 2004.
16.Weekly CPT-11 as second line treatment for small cell lung cancer patients. O. Juan, J. Muñoz, G. Esquerdo. Annals of Oncology , volume 15, Supplement 3, 2004.
17.Tratamiento con epoetinum alfa, pauta seminal (40000 ui) , en pacientes con cáncer estadio IV . Respondedores tipo I tipo II y refractarios. Esquerdo G, LLorca C, Cervera JM. Medicina paliativa vol 10, supl. I NOVIEMBRE 2003
18.Aplicación de las nuevas tecnologías a los cuidados paliativos.Cervera JM, Esquerdo G., LLorca C. Medicina paliativa vol 10, supl. I NOVIEMBRE 2003
19.Phase II study of gemcitabine (GEM) and modulated oral tegafur (TGF) in advanced carcinoma of the pancreas (ACP). Preliminary results. E. Saigi, P. Escudero, L. Cirera, M. Gallen, J.-M. Campos, I. Guasch, G. Esquerdo, R. Bastus, M. Balcells, B. Almenar. Proc Am Soc Clin Oncol 22: 2003 (abstr 1366)
20.Phase II study of epirubicin, cisplatin and modulated oral tegafur (EPT) in advanced gastric cancer (AGC) . E. Gallardo, E. Batiste-Alentorn, P. Escudero, E. Saigi, F. Losa, V. Alonso, J.-M. Campos, G. Esquerdo, I. Moreno, B. Almenar. Proc Am Soc Clin Oncol 22: 2003 (abstr 1259)
21.Treatment of platinum refractory/resistant ovarian cancer with pegylated liposomial doxorubicin hydrocloride and topotecan. Preliminary results of a phase IV study. I. Maestu, A. Galan, V. Giner, A. Yuste, A. Rodriguez, C. Bosch, G. Esquerdo, R. Llorente. Proc Am Soc Clin Oncol 22: 2003 (abstr 1948).
22.Assessment of comorbidity, symptons and functional status in advanced non small cell luna cancer elderly patients treated with gemcitabie-vinorelbine. I. Maestu, J. Muñoz, L.Gomez,A. Yubero, D. Torregosa, G. Esquerdo.Lung cancer Volumen supplement agosto 2003.
23.Schedule dependency of 5-fluorouracil (5FU) chemotherapy in patients with advanced colorectal cancer: A systematic review. E. Barrajon, G. Esquerdo, A. Lopez, C. Llorca. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 2139
24.Opiodes en el tratamiento del dolor oncológico.JM Cervera, G. Esquerdo, C. LLorca. Revista de Oncologia 2004; 6 (Supl 1).
25.Efectividad de darbopetin alfa en pacientes con tumores sólodos y anemiainducida por quimioterapia tratados en el hospital de Elda. JM. Cervera, G.Esquerdo, C.llorca. Revista de Oncologia 2004; 6 (Supl 1).
26.Efectividad de darbopetin alfa en pacientes con cáncer de mama y anemia. G. Esquerdo, J.Belon, J.R. Mel. Revista de Oncologia 2004; 6 (Supl 1).
27.Modelo de construccion de una guía para los pacientes que van a iniciar su tratamiento con quimioterapía.Gonzalez I, Esquerdo G, Cervera JM, LLorca C. Oncología clínica vol. 9 –nº 2 julio 2004.
28.Gemcitabina como agente único en el tratamiento del cáncer de mama avanzado.LLorca C, Adrover E, Esquerdo G. Oncología clínica vol. 9 –nº 2 julio 2004.
29.Aplicación de las nuevas tecnologías en oncología :la e-salud.Cervera JM, Galiana E. LLorca C. . Oncología clínica vol. 9 –nº 2 julio 2004.
30.La historia digitalizada europea (pr/Env 13606, cen/Tc251) y su aplicación en oncología.Cervera JM,Esquerdo G, LLorca C. Oncología clínica vol. 9 –nº 2 julio 2004.
31.Influence of single agent paclitaxel (TAX) schedule on the pattern of response and toxicity in patients with advanced breast and lung cancer: A systematic review. E. Barrajon, A. Lopez, E. Adrover, G. Esquerdo, C. Llorca. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 2124.
32.Phase II study of gemcitabine and vinorelbine followed by docetaxel in elderly patients wih advanced non small cell lung cancer.A Galician lung cancer group study.Firvida JL , Esquerdo G , Vazquez S .16 TH International Congress on Anticancer treatment.Febr 2005.
33.Phase II study of gemcitabine and vinorelbine followed by docetaxel in elderly patients wih advanced non small cell lung cancer. Firvida JL , Esquerdo G , Vazquez Lung Cancer Volume 49, supplement 2, July 2005.
34.Estudio fase II Across con epirrubicina cisplatino y tegafur oral modulado en cáncer gástrico avanzado.S. Martinez. E. Batiste, P. Escudero, J. Alfaro,F. Losa, V. Alonso, J.M Campos, M. Gallen, G. Esquerdo y E. Gallardo.Clinical and Translational Oncology volumen 7, Extraordinario 1, junio 2005.
35.Aranesp administrado a dosis fija cada dos semanas en el tratamiento de la anemia en pacientes con tumores sólodos.J.M Cervera, G. Esquerdo, C. LLorca y H. Briceño. Clinical and Translational Oncology volumen 7, Extraordinario 1, junio 2005.
36.Epirrubicina y docetaxel en administración simultanea en el tratamiento del cáncer de mama avanzado. C. LLorca, G. Esquerdo, J.M Cervera. Clinical and Translational Oncology volumen 7, Extraordinario 1, junio 2005.
37.Quimioterapia t radioterapia neoadyuvante en estadios II-III de cáncer de recto:Analisis de respuesta y toxicidad.G. Esquerdo, C. LLorca,J.M Cervera. Clinical and Translational Oncology volumen 7, Extraordinario 1, junio 2005.
38.Phase II study of gemcitabine and vinorelbine followed by docetaxel in elderly patients wih advanced non small cell lung cancer.A Galician lung cancer group study.Firvida JL , Esquerdo G , Vazquez S .17 TH International Congress on Anticancer treatment.Febr 2006.
39.Biweekly docetaxel and carboplatin as first line chemotherapy in advanced non small cell lung cancer (NSCLC). J. L. Fírvida, G. Esquerdo, M. Amenedo, M. Salgado, C. Llorca, A. González, E. Pérez, J. M. Cervera, M. Ramos. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 17016
40.Biweekly docetaxel and carboplatin as first line chemotherapy in advanced non small cell lung cancer (NSCLC). J. L. Fírvida, G. Esquerdo, M. Amenedo. Annals of Oncology volume 17, 2006 Supplement 9.
41. J. Galan, S. del Barco, M. Mendez, G. Esquerdo, M. G. Huarriz, E. Bandres, M. C. Gil, A. B. Paules, J. Gayo, J. Garcia-Foncillas. MAP4/OP18 mRNA expression predicts progression in patients treated with vinorelbine plus carbolpatin in advanced lung cancer patients in a Multicenter trial.Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 14088
42. G. Esquerdo, C. Llorca, J. Cervera, A. Juarez, D. Orts, A. Carrato. An assessment of cancer-related fatigue in patients (pts) with chemotherapy-induced anaemia (CIA) treated with darbepoetin alfa (DA): Comparison of two quality of life (QoL) questionnaires. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 19654.
43. E. Barrajon, A. Lopez, G. Esquerdo. Influence of single agent gemcitabine (GEM) schedule on the pattern of response and toxicity in patients with advanced pancreas, lung and breast carcinoma: A systematic review. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007:
44. E. Gaspar, J. Firvida, M. Amenedo, D. Orts, M. Salgado, C. LLorca, M. Ramos, E. Perez, J. Cervera, J. Abal 13009. Biweekly docetaxel and gemcitabine as first line chemotherapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 18147.
45.Gaspar Esquerdo, Jose María Vicent, Cristina LLorca, Antonio Galan, Jose Manuel Cervera, Vicente Giner, Asunción Juarez, David Orts y Ana Belso. Resultados preliminares de un estudio asistencial de tratamiento con oxaliplatino-capecitabina- avastin, primera línea en pacientes con cáncer colorectal metastásico. Clinical- translational oncology. Volume 9- Extraordinary 2. October 2007.
46. Estudio de toxicidad del esquema TAC (Docetaxel, doxorrubicina y ciclofosfamida) más G-CSF en pacientes con cáncer de mama estadios I-III. Cristina Llorca, Gaspar Esquerdo, Asunción Juarez y Jose Manuel Cervera. Clinical- translational oncology. Volume 9- Extraordinary 2. October 2007.
47.Gaspar Esquerdo, Cristina Llorca, Jose Manuel Cervera, Asunción Juarez, David Orts y Alfredo Carrato. Comparación de dos cuestionarios de Fatiga en pacientes con anemia inducida por quimioterapia tratados con darbopoetin alfa cada tres semanas. . Clinical- translational oncology. Volume 9- Extraordinary 2. October 2007.
48. Gaspar Esquerdo, Cristina Llorca, Jose Manuel Cervera, Asunción Juarez, David Orts y Alfredo Carrato. Experiencia del uso de darbopoetin alfa en el tratamiento de la anemia inducida por la quimioterapia en pacientes con cáncer metastásico:Efectividad e impacto en la calidad de vida. Clinical- translational oncology. Volume 9- Extraordinary 2. October 2007.
49. Gaspar Esquerdo, Jose Luis Fírvida, Margarita Amenedo, David Orts, Mercedes Salgado, Cristina LLorca, Manuel Ramos, Eva Perez, Jose Manuel Cervera y Joaquin Abal. Pauta quincenal con taxotere-gemcitabina en primera línea de cáncer de pulmón no microcítico estadio IIIB-IV. Clinical- translational oncology. Volume 9- Extraordinary 2. October 2007.
50. Galan Antonio, Del Barco Sonia, Mendez Miguel, Esquerdo Gaspar. MAP4/OP18 mrna expression predicts progression in patients treated with vinorelbine plus carboplatine in advanced lung cáncer patients in a multicenter trial. Journal of Thoracic Oncology. Volume 2. Number 8. August 2007.
51.Mendez Miguel, Andrade Jesus, Esquerdo Gaspar. Clinical experience with single agent oral vinorelbine in first line advanced non small cell lung cáncer treatment of elderly patients. . Journal of Thoracic Oncology. Volume 2. Number 8. August 2007.
52. . Gaspar Esquerdo, Jose Luis Fírvida, Margarita Amenedo, David Orts, Mercedes Salgado. Biweekly docetaxel and gemcitabine as first line chemotherapy in advanced non small cell lung cáncer. Journal of Thoracic Oncology. Volume 2. Number 8. August 2007.
53. J. L. Fírvida, G. Esquerdo, M. Amenedo, M. Salgado, C. LLorca, E. Pérez, J. Cervera Grau, M. Ramos. Biweekly docetaxel and carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Finally results of a phase II study. J Clin Oncol 26: 2008 (May 20 suppl; abstr 19097).
54. C. Castañón, V. Alonso, J. Vieitez, G. Esquerdo, R. Pérez-Carrión, C. Belda-Iniesta, M. Rubio, J. Roca, G. García, A. Salut. Clinical profile of patients with metastatic colorectal adenocarcinoma treated with bevacizumab in first-line: AVATRAN study. J Clin Oncol 26: 2008 (May 20 suppl; abstr 15119).
55.J. Cervera Grau, G. Esquerdo Galiana, M. Romero Nieto, S. Macia Escalante, A. Juarez Marroqui, C. Llorca Ferrandiz. Response to vinorelbine (VNB) as first-line chemotherapy in elderly patients with hormone-refractory prostate cancer (HRPC). J Clin Oncol 26: 2008 (May 20 suppl; abstr 16140).
56. J.M. Cervera Grau, A. Ló pez, J. Sastre, O. Juan, E. Barrajón, G. Esquerdo
Galiana, C.M. Molins, C. Llorca. PEMETREXED AS RESCUE IN UROTHELIAL CARCINOMA OFTHE BLADDER. PRELIMINAR RESULTS FROM A FOLLOW-UPIN ARCO DEL MEDITERRANEO GROUP. Annals of Oncology
. Volume 19 | Supplement 8 | September 2008
57. G. Esquerdo, M. Doménech, J. C. Bermejo, P. López, C. Pedro, K. Villadiego, M. Constenla, P. Sánchez-Rovira, J. A. Gasquet, C. A. Rodríguez; Final results of a prospective, observational study of the effectiveness of darbepoetin alfa administered every three weeks for the treatment of chemotherapy-induced anaemia in elderly patients. J Clin Oncol 27, 2009 (suppl; abstr e20654) .
58.E. Barrajon, A. Lopez, G. Esquerdo, J. M. Cervera. Cure rate in early colorectal cancer estimated from disease-free survival curves from phase III comparative clinical trials: Necessity of long follow-up. J Clin Oncol 27, 2009 (suppl; abstr e15006).
59. C. Llorca, G. Esquerdo, J. Muñoz Sr., A. Sanchez-Hernandez, J. Gómez-Codina, O. Juan Vidal, S. Maciá, S. Catot, V. Giner, F. Aparisi. Phase II study of biweekly gemcitabine and docetaxel as first-line treatment for advanced disease in elderly non-small cell lung cancer (NSCLC) patients. J Clin Oncol 28, 2010 (suppl; abstr e18066)
60.G. Esquerdo, J. Cervera, E. Barrajon, A. Juarez, C. Llorca, N. Diaz, A. Lopez, R. Peiro. Obser vational study to evaluate the possible association between serum levels of C-reactive protein and response to the treatment of chemotherapy-induced anemia in solid tumors (Pronost Study). J Clin Oncol 28, 2010 (suppl; abstr e19546) .
61. V. Giner, O. Juan Vidal, J. Muñoz Sr., G. Esquerdo, A. Sanchez-Hernandez, J. Gómez-Codina, F. Aparisi, S. Maciá, A. López Jiménez, S. Catot Phase II study of biweekly gemcitabine and docetaxel as first-line treatment for advanced disease in non-small cell lung cancer (NSCLC) patients with ECOG performance status 2. J Clin Oncol 28, 2010 (suppl; abstr e18083) .
62. A. Lopez Jimenez, G. Esquerdo, E. Barrajon, L. Del Rio Pazos, J. Cervera, N. Diaz, C. Angeles Oyonarte.Outcomes of small cell lung cancer (SCLC) patients treated with second-line chemotherapy (SL) with CPT-11: A retrospective analysis. J Clin Oncol 28, 2010 (suppl; abstr e18144) .
63. R. A. Pazo Cid, G. Esquerdo, T. Puertolas, V. Calderero, I. Gil, J. Lao, E. Millastre, M. Alvarez-Alejandro, J. Madani, A. Anton. Bevacizumab (BVZ) as second-line treatment after sorafenib (SFB) progression in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 28, 2010 (suppl; abstr e14619)
64. J. Cervera Grau, E. Gonzalez-Billalabeitia, A. Lopez, O. Juan Vidal, J. Satre, E. Barrajon, G. Esquerdo, C. Molins, S. Maciá, C. D. RolfoDiverse long-time progression-free survival (PFS) and overall survival (OS), based on metastasis location, in metastatic urothelial carcinoma (MUC) patients treated with pemetexed (P) in monotherapy: Results from a longer follow-up of Arco del Mediterraneo Group. J Clin Oncol 28, 2010 (suppl; abstr e15120)
65.Nuria Piera, Jose Muñoz, Gaspar Esquerdo, José Gomez-codina. Eficacia y tolerancia de gemcitabina y docetaxel quincenal en ancianos con cáncer de pulmón no microcítico estadio avanzado en primera línea de tratamiento: Estudio Fase II. I Simposio Nacional SEOM 2010.
66. Gaspar Esquerdo, Jose Manuel Cervera, Enrique Barrajón. Estudio epidemiológico para evaluar la asociación entre niveles séricos de proteína C reactiva y respuesta a la anemia inducida por quimioterapia en pacientes con cáncer de pulmón (Estudio Pronost). I Simposio Nacional SEOM 2010.
67. Óscar Juan, Joaquin Aparisi, Alfredo Sanchez, Vicente Giner, Jose Muñoz, Gaspar Esquerdo. Estudio aleatorizado fase II , abierto multicéntrico de tratamiento secuencial con docetaxel y erlotinib intermitente frente a erlotinib en pacientes con carcinoma microcítico de pulmón avanzado tras fallo de a un tratamiento quimioterápico previo.XIII Congreso de la Sociedad de Oncología Médica. Málaga 2011.
68. F. Aparisi, J. Garcia Sanchez, A. Sanchez-Hernandez, V. Giner, J. Muñoz-Langa, G. Esquerdo, A. López Jiménez, J. Garde. A multicenter, open, randomized, phase II study to investigate the sequential administration of docetaxel and intermittent erlotinib versus erlotinib as a second-line therapy for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 29: 2011 (suppl; abstr e18036).
69. G. Esquerdo, Jose Manuel Cervera, Enrique Barrajón.Observational study to evaluate the possible association between serum levels of C-reactive protein and response to the treatment of chemotherapy-induced anemia in solid tumors: Pronost study. Supportive Care e19714 J Clin Oncol 29: 2011 (suppl; abstr e19714)
70. Manuel Santos Ortega, Gaspar Esquerdo, Jose Manuel Cervera Grau, Enrique Barrajon, Silvia Rodriguez Villalva, Marina De Piaggio, Rafael Peiro, Rita De Sanctis, Macarena Paz Espinoza Venegas. Phase II study: Docetaxel-cisplatin and pro drug tegafur (TPF) as neoadjuvant treatment in advanced patients with head and neck cancer (HNC): Results and correlation between tandem magnesium/creatinine and toxicity. J Clin Oncol 30, 2012 (suppl; abstr e16025)
71. Francisco Aparisi, Alfredo Sanchez-Hernandez, Vicente Giner, José Muñoz-Langa, Gaspar Esquerdo, Antonio López Jiménez, Javier Garde, Jose Garcia Sanchez, Oscar Juan Vidal.
Clinical benefits of sequential administration of docetaxel and intermittent erlotinib as a second-line therapy for advanced non-small cell lung cancer (NSCLC): A phase II randomized study. J Clin Oncol 30, 2012 (suppl; abstr e18049).
72. Sanchez-Hernandez, Jose Garcia Sanchez, Remei Blanco, Sonia Maciá, Gaspar Esquerdo, Francisco Aparisi, Javier Garde. Quantification of circulating endothelilial cells (CECs) as a predictor of response to chemotherapy with platinum and pemetrexed in patients with nonsquamous non-small cell lung carcinoma. . J Clin Oncol 30, 2012 (suppl; abstr e18053).
73. Manuel Sastre, Enrique Barrajon , Gaspar Esquerdo, Carmen Molins. Long-term progression-free survival (PFS) and overall survival to pemetrexed as single agent in metasyatic urotelial carcinoma: A spanish Oncology Genitourinary Group (SOGUG) sistematyc review. . J Clin Oncol 30, 2012 (suppl; abstr 4587).
74. JM Cervera-Grau, Gaspar Esquerdo, Enrique Barrajon, Rafael Peiro, Manuel Santos Ortega, Silvia Rodriguez Villalva, Marina De Piaggio, Macarena Paz Espinoza Venegas, Ana Belen Montiel Rayo. Hyponatremia and cancer: Results of a retrospective analysis of 45 patients treated with a short course of low-dose tolvapan. J Clin Oncol 31, 2013 (suppl; abstr e20705)
75. Gaspar Esquerdo, Jose Luis Fírvida, Javier Garde, Jose Manuel Cervera, MC. Areses, Enrique Barrajon, Macarena Espinoza, Rafael Peiro, Belen Montiel, Jose Garcia. Efficacy and safety of carboplatin and pemetrexed for the first line treatment of unfit patients to receive cisplatin with nonsquamous non small cell lung cancer. Sidney 2013, congreso mundial de cáncer de pulmón